The chlamydia infection diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $1.35 billion in 2023 to $1.43 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The increase in the historic period can be linked to several factors, including a rise in sexual activity, enhancements in healthcare infrastructure, government initiatives and funding, greater awareness and screening programs, and a higher prevalence of chlamydia infections.
The chlamydia infection diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $1.79 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth during the forecast period is driven by awareness campaigns, substantial healthcare expenditure, a rise in infections among young adults, regulatory approvals, the expansion of healthcare infrastructure, and a growing incidence of antibiotic resistance. Key trends expected in the forecast period include advancements in diagnostic technologies, the creation of point-of-care tests, collaborations and partnerships, the development of effective treatment options, and ongoing technological progress.
The growing prevalence of sexually transmitted infections (STIs) is projected to drive the expansion of the market for chlamydia infection diagnostics and treatments. STIs are infections commonly transmitted through sexual activities, including vaginal, anal, or oral sex. Factors contributing to the rise in STIs include inconsistent use of barrier methods, insufficient awareness and education about safe sex, increased global travel and migration, and potentially reduced funding for public health prevention programs. Diagnostics and treatments for chlamydia are crucial for managing STIs, allowing for early detection and effective treatment to prevent complications and further transmission. For example, the World Health Organization reported in May 2024 that over 1 million curable STIs are acquired daily worldwide among individuals aged 15-49, with many of these infections being asymptomatic. Consequently, the increasing global incidence of STIs is fueling the growth of the chlamydia infection diagnostics and therapeutics market.
Leading companies in the chlamydia infection treatment market are focusing on developing advanced diagnostic technologies, such as fully automated, high-throughput infectious disease molecular diagnostic platforms, to improve diagnostic accuracy and streamline laboratory workflows. These platforms are cutting-edge systems designed to enhance the detection of infectious diseases. For example, in May 2022, Becton, Dickinson, and Company (BD), a US-based medical company, introduced the BD CORTM MX instrument, a fully automated, high-throughput infectious disease molecular diagnostic platform. This advanced device aims to improve diagnostic capabilities in clinical laboratories by offering automated molecular testing solutions. The BD CORTM MX/PX System fully automates the entire molecular laboratory workflow, from sample processing to delivering diagnostic test results, and is designed for high-throughput laboratories. It detects the three most prevalent non-viral sexually transmitted infections (STIs), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV), in a single test.
In April 2022, Chiricahua Community Health Centers Inc. (CCHCI), a US-based healthcare provider, partnered with The Body Agency Collective (TBAC) and Visby Medical, Inc. to enhance STI diagnosis and treatment. This collaboration will utilize the Sexual Health Click Test, a PCR diagnostic device capable of detecting gonorrhea, chlamydia, and trichomoniasis, which are three prevalent and treatable STIs in women. The Body Agency Collective (TBAC) is a US-based foundation dedicated to providing accessible sexual and reproductive health education and services to women and girls, while Visby Medical, Inc. is a US-based company specializing in innovative diagnostic solutions for improving chlamydia diagnosis and treatment.
Major companies operating in the chlamydia infection diagnostics and therapeutics market are F. Hoffman La-Roche Ltd, Merck & Co. Inc., AbbVie Inc, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca, Abbott Laboratory, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Danaher Corporation, Gilead Sciences, Siemens Healthineers, Becton Dickinson and Company, Accelerate Diagnostics, Hologic Inc., Biomerieux, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin SpA, Luminex Corporation, Meridian Bioscience, Trinity Biotech Plc, Copan Diagnostics, Hain Lifescience GmbH.
North America was the largest region in the chlamydia infection diagnostics and therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chlamydia infection diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chlamydia infection diagnostics and therapeutics encompass the full spectrum of identifying and treating infections caused by the bacterium Chlamydia trachomatis. This includes the diagnostic techniques used to detect the infection and the therapeutic methods employed to treat it. The goal of combining chlamydia infection diagnostics and therapeutics is to accurately identify infections, provide effective treatments, prevent complications, and reduce the spread of the disease through coordinated healthcare strategies.
The primary types of chlamydia infection diagnostics and therapeutics include nucleic acid amplification tests (NAATS), direct fluorescent tests, and a range of antibiotics such as macrolides, quinolones, sulfonamides, tetracyclines, and aminopenicillins. Nucleic acid amplification tests (NAATS) are advanced diagnostic tools designed to detect the genetic material of Chlamydia bacteria. The infections can be categorized into genital chlamydia infection, rectal chlamydia infection, and ocular chlamydia infection. These diagnostics and therapeutics are used in various settings, including hospitals, specialty clinics, diagnostic centers, and pharmacies (hospital pharmacies, drugstores, retail pharmacies, and online pharmacies).
The chlamydia infection diagnostics and therapeutics market research report is one of a series of new reports that provides chlamydia infection diagnostics and therapeutics market statistics, including chlamydia infection diagnostics and therapeutics industry global market size, regional shares, competitors with a chlamydia infection diagnostics and therapeutics market share, detailed chlamydia infection diagnostics and therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics and therapeutics industry. This chlamydia infection diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chlamydia infection diagnostics and therapeutics market consists of revenues earned by entities providing services such as swab testing, molecular testing, serological tests, urine testing, direct fluorescent antibody (DFA) testing, and enzyme-linked immunosorbent assays (ELISA). The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia infection diagnostics and therapeutics market also includes sales of nucleic acid amplification tests (NAAT) kits, chlamydia culture kits, enzyme-linked immunosorbent assay (ELISA) kits, polymerase chain reaction (PCR) kits, and antibiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The chlamydia infection diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $1.79 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth during the forecast period is driven by awareness campaigns, substantial healthcare expenditure, a rise in infections among young adults, regulatory approvals, the expansion of healthcare infrastructure, and a growing incidence of antibiotic resistance. Key trends expected in the forecast period include advancements in diagnostic technologies, the creation of point-of-care tests, collaborations and partnerships, the development of effective treatment options, and ongoing technological progress.
The growing prevalence of sexually transmitted infections (STIs) is projected to drive the expansion of the market for chlamydia infection diagnostics and treatments. STIs are infections commonly transmitted through sexual activities, including vaginal, anal, or oral sex. Factors contributing to the rise in STIs include inconsistent use of barrier methods, insufficient awareness and education about safe sex, increased global travel and migration, and potentially reduced funding for public health prevention programs. Diagnostics and treatments for chlamydia are crucial for managing STIs, allowing for early detection and effective treatment to prevent complications and further transmission. For example, the World Health Organization reported in May 2024 that over 1 million curable STIs are acquired daily worldwide among individuals aged 15-49, with many of these infections being asymptomatic. Consequently, the increasing global incidence of STIs is fueling the growth of the chlamydia infection diagnostics and therapeutics market.
Leading companies in the chlamydia infection treatment market are focusing on developing advanced diagnostic technologies, such as fully automated, high-throughput infectious disease molecular diagnostic platforms, to improve diagnostic accuracy and streamline laboratory workflows. These platforms are cutting-edge systems designed to enhance the detection of infectious diseases. For example, in May 2022, Becton, Dickinson, and Company (BD), a US-based medical company, introduced the BD CORTM MX instrument, a fully automated, high-throughput infectious disease molecular diagnostic platform. This advanced device aims to improve diagnostic capabilities in clinical laboratories by offering automated molecular testing solutions. The BD CORTM MX/PX System fully automates the entire molecular laboratory workflow, from sample processing to delivering diagnostic test results, and is designed for high-throughput laboratories. It detects the three most prevalent non-viral sexually transmitted infections (STIs), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV), in a single test.
In April 2022, Chiricahua Community Health Centers Inc. (CCHCI), a US-based healthcare provider, partnered with The Body Agency Collective (TBAC) and Visby Medical, Inc. to enhance STI diagnosis and treatment. This collaboration will utilize the Sexual Health Click Test, a PCR diagnostic device capable of detecting gonorrhea, chlamydia, and trichomoniasis, which are three prevalent and treatable STIs in women. The Body Agency Collective (TBAC) is a US-based foundation dedicated to providing accessible sexual and reproductive health education and services to women and girls, while Visby Medical, Inc. is a US-based company specializing in innovative diagnostic solutions for improving chlamydia diagnosis and treatment.
Major companies operating in the chlamydia infection diagnostics and therapeutics market are F. Hoffman La-Roche Ltd, Merck & Co. Inc., AbbVie Inc, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca, Abbott Laboratory, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Danaher Corporation, Gilead Sciences, Siemens Healthineers, Becton Dickinson and Company, Accelerate Diagnostics, Hologic Inc., Biomerieux, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin SpA, Luminex Corporation, Meridian Bioscience, Trinity Biotech Plc, Copan Diagnostics, Hain Lifescience GmbH.
North America was the largest region in the chlamydia infection diagnostics and therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chlamydia infection diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chlamydia infection diagnostics and therapeutics encompass the full spectrum of identifying and treating infections caused by the bacterium Chlamydia trachomatis. This includes the diagnostic techniques used to detect the infection and the therapeutic methods employed to treat it. The goal of combining chlamydia infection diagnostics and therapeutics is to accurately identify infections, provide effective treatments, prevent complications, and reduce the spread of the disease through coordinated healthcare strategies.
The primary types of chlamydia infection diagnostics and therapeutics include nucleic acid amplification tests (NAATS), direct fluorescent tests, and a range of antibiotics such as macrolides, quinolones, sulfonamides, tetracyclines, and aminopenicillins. Nucleic acid amplification tests (NAATS) are advanced diagnostic tools designed to detect the genetic material of Chlamydia bacteria. The infections can be categorized into genital chlamydia infection, rectal chlamydia infection, and ocular chlamydia infection. These diagnostics and therapeutics are used in various settings, including hospitals, specialty clinics, diagnostic centers, and pharmacies (hospital pharmacies, drugstores, retail pharmacies, and online pharmacies).
The chlamydia infection diagnostics and therapeutics market research report is one of a series of new reports that provides chlamydia infection diagnostics and therapeutics market statistics, including chlamydia infection diagnostics and therapeutics industry global market size, regional shares, competitors with a chlamydia infection diagnostics and therapeutics market share, detailed chlamydia infection diagnostics and therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics and therapeutics industry. This chlamydia infection diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chlamydia infection diagnostics and therapeutics market consists of revenues earned by entities providing services such as swab testing, molecular testing, serological tests, urine testing, direct fluorescent antibody (DFA) testing, and enzyme-linked immunosorbent assays (ELISA). The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia infection diagnostics and therapeutics market also includes sales of nucleic acid amplification tests (NAAT) kits, chlamydia culture kits, enzyme-linked immunosorbent assay (ELISA) kits, polymerase chain reaction (PCR) kits, and antibiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chlamydia Infection Diagnostics Market Characteristics3. Chlamydia Infection Diagnostics Market Trends and Strategies32. Global Chlamydia Infection Diagnostics Market Competitive Benchmarking33. Global Chlamydia Infection Diagnostics Market Competitive Dashboard34. Key Mergers and Acquisitions in the Chlamydia Infection Diagnostics Market
4. Chlamydia Infection Diagnostics Market - Macro Economic Scenario
5. Global Chlamydia Infection Diagnostics Market Size and Growth
6. Chlamydia Infection Diagnostics Market Segmentation
7. Chlamydia Infection Diagnostics Market Regional and Country Analysis
8. Asia-Pacific Chlamydia Infection Diagnostics Market
9. China Chlamydia Infection Diagnostics Market
10. India Chlamydia Infection Diagnostics Market
11. Japan Chlamydia Infection Diagnostics Market
12. Australia Chlamydia Infection Diagnostics Market
13. Indonesia Chlamydia Infection Diagnostics Market
14. South Korea Chlamydia Infection Diagnostics Market
15. Western Europe Chlamydia Infection Diagnostics Market
16. UK Chlamydia Infection Diagnostics Market
17. Germany Chlamydia Infection Diagnostics Market
18. France Chlamydia Infection Diagnostics Market
19. Italy Chlamydia Infection Diagnostics Market
20. Spain Chlamydia Infection Diagnostics Market
21. Eastern Europe Chlamydia Infection Diagnostics Market
22. Russia Chlamydia Infection Diagnostics Market
23. North America Chlamydia Infection Diagnostics Market
24. USA Chlamydia Infection Diagnostics Market
25. Canada Chlamydia Infection Diagnostics Market
26. South America Chlamydia Infection Diagnostics Market
27. Brazil Chlamydia Infection Diagnostics Market
28. Middle East Chlamydia Infection Diagnostics Market
29. Africa Chlamydia Infection Diagnostics Market
30. Chlamydia Infection Diagnostics Market Competitive Landscape and Company Profiles
31. Chlamydia Infection Diagnostics Market Other Major and Innovative Companies
35. Chlamydia Infection Diagnostics Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Chlamydia Infection Diagnostics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chlamydia infection diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chlamydia infection diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Test Type: Culture Test; Nucleic Acid Amplification Test (NAAT); Direct Fluorescent Antibody Test; Serology Test; Other Test Types2) By Type Of Infections: Genital Chlamydia Infection; Rectal Chlamydia Infection; Ocular Chlamydia Infection
3) By Application: Hospitals; Specialty Clinics; Diagnostic Centers
4) By End User: Diagnostics; Therapeutics
Key Companies Mentioned: Roche Diagnostics; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Roche Diagnostics
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers
- Becton, Dickinson and Company
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Hologic Inc.
- Illumina Inc.
- bioMérieux SA
- QuidelOrtho Corporation
- Bio-Rad Laboratories, Inc.
- Qiagen N.V.
- DiaSorin S.p.A.
- Randox Laboratories Ltd.
- Cepheid
- Meridian Bioscience Inc.
- Sekisui Diagnostics
- Copan Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | September 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 1.43 Billion |
| Forecasted Market Value ( USD | $ 1.79 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
